Chart positions today · Canada
Not on the United States charts we track today.
Not on the United Kingdom charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the New Zealand charts we track today.
Not on the Ireland charts we track today.
Not on the India charts we track today.
Not on the Japan charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like Scrip Podcasts, try…
Ranking history · Canada
Latest episodes
-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.19, 2026
October 19, 2026 · 17 min本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括:Tremfya从Stelara的余烬中崛起;辉瑞将成熟品牌作为试验田;中国科研力量在第三季度交易中大放异彩;Argenx在自身免疫领域取得进展与遭遇挫折;日本力图重振生物制药竞争力。 Story links: https://insights.citeline.co…
-
Scrip's Five Must-Know Things - Oct. 19, 2026
October 19, 2026 · 17 minJoin us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business…
-
Scrip's Five Must-Know Things - Oct. 13, 2026
October 15, 2026 · 16 minJoin us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business…
-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.14, 2026
October 15, 2026 · 18 min本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括:中国带来的竞争威胁;第三季度并购活动降温;新型肺炎球菌疫苗竞争者;西班牙生物技术公司的战略;以及盐野义制药20亿美元的收购案。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-mu…
-
Rethinking Success in Neuroscience Clinical Development
October 12, 2026 · 13 minDespite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult. As…
Show 7 more episodesShow fewer episodes
-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.5, 2026
October 5, 2026 · 17 min本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年10月2日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 谁在引领今年的并购步伐;罗氏(Roche)的研发管线重整;湿性黄斑变性(wet AMD)市场的洗牌;默克公司(Merck & Co.)撤回I-DXd申报;以及默克将Recarbio从市场上撤回。 Story links: https://insights.citelin…
-
Scrip's Five Must-Know Things - Oct. 5, 2026
October 5, 2026 · 16 minAudio roundup of selected biopharma industry content from Scrip over the business week ended Oct. 2, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—who’s setting the M&A pace this…
-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Sept. 25, 2026
September 28, 2026 · 19 min本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年9月25日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 中国带来的变革效应;诺和诺德的新战略;罗氏的抗肥胖新药;安进在舍格伦综合征治疗领域的胜利;以及中国潜在的重磅药物。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-kn…
-
Scrip's Five Must-Know Things - Sept. 28, 2026
September 28, 2026 · 18 minAudio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 25, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—China’s transforming effect…
-
Assessing the current dealmaking environment for psychedelic medicine.
September 24, 2026 · 20 minJoseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways'…
-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Sept. 14, 2026
September 14, 2026 · 20 min本期播客内容来自《Scrip》杂志,精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 本期内容包括:近期III期试验失败后,心血管领域研发的下一步动向;全球销量前十的药物中有九款在第二季度实现连续增长;阿斯利康的首创性慢性阻塞性肺病(COPD)药物在III期试验中表现优于Dupixent;Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成…
-
Scrip's Five Must-Know Things - Sept, 14, 2026
September 14, 2026 · 19 minAudio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular…

United States
Australia
Brazil
Germany
India
Ireland
Japan
Mexico
New Zealand
Philippines
South Africa
United Kingdom